Chronic coronary syndrome. Chronic ischemic heart disease
Conditions
Interventions
Intervention 1: Intervention group: Curcumin soft capsule (Turmepro produced by Gol Daro Pharmaceutical Company) 250 mg every 8 hours for 8 weeks. Intervention 2: Control group: placebo soft capsule (
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age above 18 years Suffering from chronic coronary syndrome according to the guidelines of the European Society of Cardiology (ESC) published in 2019 Full consent to participate in the study
Exclusion criteria
Exclusion criteria: Using any product containing curcumin and turmeric during the last weekcontent_copyshare History of acute coronary syndrome in the last 6 months Suffering from any other heart disorders including myocarditis, cardiomyopathy and severe valvular disorder Having hyperthyroidism Having kidney failure (creatinine clearance less than 60 ml/min) Liver disorder (Child-pugh score stage B or C) Using psychoactive drugs (alcohol, marijuana, opioids, cocaine, dextroamphetamine) The use of any anti-inflammatory or antioxidant drug (corticosteroid, NSAID, vitamins C or E, coenzyme Q10 products, immunosuppressive drugs, ...) from one week before the start of the intervention Suffering from other cognitive disorders History of allergy to curcumin Difficulty hearing or speaking pregnancy breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of cholesterol, LDL, HDL, TG, FBS, hs_CRP and uric acid and Changing the score of the SAQ questionnaire. Timepoint: Before and after the end of the intervention. Method of measurement: Seattle Angina Questionnaire (SAQ) and checking biomarkers of cholesterol, LDL, HDL, TG, FBS, hs_CRP and uric acid in blood samples. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRasool Soltani
Esfahan University of Medical Sciences
Outcome results
None listed